7月 2026
- 首頁
- KYinno
7月 2026KYinno的市場佔有率分析
Kyinno's customized cell line construction offers specific mutations, resistance profiles & reporter systems for targeted drug development.
KYinno(包含公司地區)
查看更多網站流量與參與度資訊- kyinno.com
KYinno截至 7月 2026 的總收入為 2M - 5M
KYinno 熱門網域產生的總收入
KYinno 熱門網域 3 年內的總收入
KYinno 熱門網域的總收入
KYinno的熱門網域總造訪量
了解KYinno市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
KYinno的熱門網域平均造訪時長
分析KYinno參與度指標。
過去 3 個月平均造訪時長
子公司細目
KYinno的熱門網域平均頁面瀏覽量
了解KYinno如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自KYinno
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Kyinno Biotechnology Co. is developing series of high-quality KLK2 / KLK3 cell lines.Based on these targets, the cell biology division of Kyinno Biotechnology has developed a series of high-quality KLK2 / KLK3 cell lines, providing precise and efficient experimental model systems for scientific research and drug screening.
4月 13, 2026閱讀更多
新聞Kyinno Biotechnology Co. launches TOP1-R364H-KI gene-edited cell line.To address this challenge, Kyinno Biotechnology has successfully developed the TOP1-R364H-KI gene-edited cell line.
4月 13, 2026閱讀更多
新聞Kyinno Biotechnology Co. received financing of $35M in Series B on Dec 15th '25.Artery Network learned at the first opportunity that on December 15, Kyinno Biotechnology, a biotechnology company dedicated to the R&D of next-generation bispecific and multispecific antibody therapeutics, announced the successful completion of its Series B financing, raising nearly USD 35 million.
12月 21, 2025閱讀更多
查看所有KYinno信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
